Technology

Insight

TianLi Biotech develops small molecule drug treatments for respiratory diseases including interstitial pulmonary fibrosis (IPF), severe asthma and chronic obstructive pulmonary disease (COPD) that selectively inhibit the signaling pathways downstream of the fibrogenic growth factor TGF-β.

The research led by Professor Alastair Stewart at The University of Melbourne has established that isoforms (δ and ε) of the regulatory protein casein kinase 1 (CK1), are involved in the actions of TGF-β.

Our research has been published in leading peer reviewed journals

View Publications

Global inhibition of TGF-β is not considered safe for chronic disease. TGFβ is essential for normal function, and completely blocking it risks severe autoimmune disease and cardiac toxicity. Targeting the casein kinase pathway would avoid these toxicities.

Small molecule inhibitors of CK1 δ/ε demonstrate that these kinases mediate TGF-β induced fibrogenesis and glucocorticoid resistance with specificity of contribution demonstrated using siRNA against CK1 δ/ε. The selective modulation of TGFβ activity provides an opportunity to develop inhalational and systemic treatments for certain pulmonary diseases such as IPF, asthma and COPD.

Target validation with known a inhibitor of CK1 δ/ε, PF670642, has been shown to attenuate TGFβ induced expression of fibrogenic genes in airway epithelial cellsin vitro.

Efficacy has also been established in mouse models, where PF670462 has been shown to reduce bleomycin or virally-induced inflammation and lung damage, and to restore steroid activity in virally infected, allergen-challenged mice.

TianLi Biotech is growing a significant IP portfolio protecting casein kinase inhibitors for respiratory and other diseases

For information on TianLi Biotech and the company development program please contact us via:
info@tlbiotech.com.au

TianLi Biotech

Website designed by
Fifth Castle Media